首页> 外文会议>World biomaterials congress >The potential use of allogeneic platelet rich plasma for large bone defect treatment: Immunogenicity and defect healing efficacy
【24h】

The potential use of allogeneic platelet rich plasma for large bone defect treatment: Immunogenicity and defect healing efficacy

机译:同种异体血小板富血浆的潜在用途大骨缺损治疗:免疫原性和缺陷愈合疗效

获取原文

摘要

Platelet rich plasma (PRP) can be easily isolated from peripheral blood and used as an excellent nature biomaterial with the beneficial effect to promote bone defect healing. However, the clinical application of autologous PRP is harassed by controversial therapeutic outcome, due to highly variable PRP quality among patients. Alternatively, allogeneic PRP prepared from well-characterized donors may generate more consistent and reliable therapeutic effect. Moreover, using allogeneic PRP can avoid additional procedure to harvest large quantity of blood, eliminating extra health burdens on patients, especially in trauma conditions. However, the use of allogeneic PRP for bone defect treatment is generally less investigated, especially for its immunogenicity in such application. Here, we meticulously investigated the immunogenicity of allogeneic PRP in the absence of major histocompatibility complex (MHC) matching and evaluated its healing efficacy for critical sized defects treatment. The intramuscular injection of allogeneic PRP to rabbits did not trigger severe and chronic immuno-response, evidenced by little change in muscular tissue microstructure and CD4+ /CD8+ T lymphocyte subpopulation in peripheral blood. The implantation of allogeneic PRP mediated deproteinized bone matrix (DPB) constructs (PRP+DPB) successfully bridged 1.5 cm segmental radial defects in rabbits, achieving similar healing capacity as autologous MSC loaded DPB constructs (MSC+DPB), with greater bone formation (1.1-1.5x, p<0.05) and vascularization (1.3-1.6x, p<0.05) than DPB alone, shown by histomorphometric analysis, bone mineral density measurement and radionuclide bone imaging. Furthermore, the implantation of both allogeneic PRP and autologous MSC mediated DPB constructs (PRP+MSC+DPB) resulted in the most robust bone regeneration (1.2-2.1x, p<0.05) and vascularization (1.3-2.0x, p<0.05) than others (PRP+DPB, MSC+DPB or DPB alone).
机译:富含血小板的血浆(PRP)可从外周血容易地分离并用作优异的性质的生物材料与所述有益效果,以促进骨缺损愈合。然而,自体PRP的临床应用是有争议的治疗效果骚扰,由于患者的高度可变的PRP质量。可替代地,同种异体PRP从充分表征的供体来制备可产生更一致和可靠的治疗效果。此外,使用异体PRP可避免额外的过程收获的血液量大,消除患者额外的健康负担,尤其是在创伤条件。然而,使用骨缺损治疗同种异体PRP的一般较少研究,特别是对于其在这样的应用的免疫原性。在这里,我们精心研究了同种异体PRP的免疫原性在没有主要组织相容性复合体(MHC)的匹配并评估其愈合疗效的关键尺寸的缺陷处理。同种异体PRP的肌内注射到兔子没有触发严重的慢性免疫反应,通过在外周血中肌肉组织的微结构和CD4 + / CD8 + T淋巴细胞亚群变化不大证明。同种异体PRP的注入介导的脱蛋白的骨基质(DPB)构建体(PRP + DPB)成功地桥接1.5厘米节段性兔径向缺陷,实现了类似的愈合能力的自体MSC装载DPB构建体(MSC + DPB),具有更大的骨形成(1.1 -1.5x,p <0.05)和血管(1.3-1.6x,p <0.05)比单独DPB,通过组织形态学分析,骨密度测量和放射性核素骨显像所示。此外,两个同种异体PRP和自体MSC介导的DPB构建体(PRP + MSC + DPB)的注入导致最稳健的骨再生(1.2-2.1x,P <0.05)和血管(1.3-2.0x,P <0.05)比别人(PRP + DPB,MSC + DPB或单独DPB)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号